Breast cancer breakthrough? trial tests skipping surgery for some women
NCT ID NCT07357948
First seen Jan 24, 2026
Summary
This study tests whether women with triple-negative breast cancer who have a complete response to chemo-immunotherapy can safely skip breast and lymph node surgery. 150 participants will be randomly assigned to either standard treatment with surgery or standard treatment without surgery. The goal is to see if avoiding surgery leads to similar cancer control with fewer complications and better quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Georges-François Leclerc
Dijon, 21000, France
Contact
Contact
-
Hôpital Tenon
Paris, 75020, France
Contact
Contact
-
Institut Curie Saint-Cloud
Saint-Cloud, 92210, France
Contact
Contact
-
Institut Curie-Paris
Paris, 75005, France
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
omission of surgery
What this could lead to
If successful, this could allow some women with triple-negative breast cancer to avoid breast and lymph node surgery after a complete response to chemo-immunotherapy, reducing side effects and improving quality of life.
What could go wrong
This is a phase 2 trial with only 150 participants, so results are preliminary. Skipping surgery might increase the risk of cancer returning in the breast or lymph nodes, and long-term safety is not yet known.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.